Swiss Life Asset Management’s Theravance Biopharma TBPH Stock Holding History

Swiss Life Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$181K	Buy	+10,619	New	+$176K	﹤0.01%	1543

Other funds holding TBPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Swiss Life Asset Management's TBPH Position: Q2 2026 in Review

Swiss Life Asset Management opened a new position in Theravance Biopharma (TBPH) in Q2 2026: 10,619 shares worth $181K. The stake represents ﹤0.01% of the portfolio and ranks #1543 among its holdings.

91 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

Swiss Life Asset Management held 10,619 shares of Theravance Biopharma worth $181K as of Q2 2026.
Theravance Biopharma was a new Swiss Life Asset Management position in Q2 2026.
Theravance Biopharma made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #1543 holding.
91 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.